ELI LILLY & Co is 65.9x more valuable than GENMAB A/S by market capitalization ($1.072 T vs $16.27 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | GMAB | LLY |
|---|---|---|
| Market cap | $16.27 B | $1.072 T |
| US-listed rank | #696 | #10 |
| Revenue (latest FY) | - | $65.18B |
| Net income (latest FY) | - | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 51.9 |
| SEC filings | 540 | 989 |
ELI LILLY & Co is 65.9x more valuable than GENMAB A/S by market capitalization ($1.072 T vs $16.27 B).
Full pages: GENMAB A/S and ELI LILLY & Co, or browse the full rankings.